ClinicalTrials.gg
CompletedNCT03636659Updated Aug 26, 2019

Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition

A Phase 1 interventional study of Amphotericin B Liposome and AmBisome (Amphotericin B) Liposome in Visceral Leishmaniasis, sponsored by Aurobindo Pharma Ltd. Completed at 3 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-08-26.

Sponsored by Aurobindo Pharma Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2019, 7 years 7 months ago, and no results have been posted to the registry.
  • Registered 3 months after the study started (first participant enrolled May 2018, registered Aug 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing Amphotericin B in Leishmaniasis, Visceral — none open to participants now, none under way, none of them phase 3. Amphotericin B · Leishmaniasis, Visceral.

Enrollment
9th of 13
140 · median 280
Started
2018
with 1 other
Phase 1
Only one
of the 13
Registered
12th of 13
by date
Lead sponsor
1 of 13
Aurobindo Pharma Ltd

Among the 13 studies testing Amphotericin B in Leishmaniasis, Visceral, this one is the 9th largest by enrollment, is one of 2 that started in 2018, is the only one in phase 1, and was the 12th registered.

Leishmaniasis, Visceral

68 studies on the registry are indexed under Leishmaniasis, Visceral; 7 are open to participants now.

Browse Leishmaniasis, Visceral studies →

Open to participants now

None of the 13 studies testing Amphotericin B in Leishmaniasis, Visceral is open now. The open studies under Leishmaniasis, Visceral, anywhere →

About Amphotericin B

Amphotericin B: first FDA approval 1964 (FUNGIZONE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 7 Leishmaniasis, Visceral studies recruiting now, 2 set no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing Amphotericin B in Leishmaniasis, Visceral as a file.
02

Study summary

The primary objective is to determine clinical bioequivalence of Amphotericin B liposome for injection of Auromedics Pharma LLC, USA and AmBisome (Amphotericin B) liposome for injection of Astellas Pharma US, Inc., in patients with Visceral Leishmaniasis under fed condition

Read the detailed description

Multi-Center, Open-Label, Randomized, Two treatment, Parallel, Single period, Multiple-Dose, Steady state, Global Bioequivalence study of Amphotericin B Liposome for Injection 50mg /vial of Auromedics Pharma LLC, USA and AmBisome (Amphotericin B) Liposome for Injection 50mg/vial of Astellas Pharma US, inc. in patients with Visceral Leishmaniasis under fed condition.Sufficient number of patients will be enrolled to have 140 evaluable patients. (90 to 100 patients from India and 40 to 50 patients from Bangladesh).

03

Conditions studied

  • Visceral Leishmaniasis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients aged between 18 to 65 years (both inclusive)
  • Clinical signs and symptoms of Visceral Leishmaniasis (fever of over 2 weeks duration, weight loss and splenomegaly)
  • Presence of amastigotes (Leishmania Donovani bodies) at screening detected by rK39 dipstick test.
  • Female subjects of must have a negative serum pregnancy test at enrolment and be willing to use a reliable method of , i.e. barrier method, intrauterine device, or tubal ligation.
  • Ability to comply with all study requirements.
  • Patients with ≥ 6.0 g/dl
  • Patients with count ≥ 60,000/mm3
  • Patients should be immunocompetent (e.g., white blood cell count ≥ 2500/ mm3)
  • Patients and/ or LAR must be give written
  • Patients with clinically acceptable results from all the screening laboratory parameters and investigations.

Exclusion criteria

Exclusion Criteria:

  • Known allergy or reactions to any components of conventional or liposomal Amphotericin B formulations.
  • Any condition which the investigator thinks may prevent the patient from completing the study therapy and subsequent follow-up.
  • Pregnant or lactating women
  • Patients requiring dose adjustment during the study.
  • Serum creatinine concentration greater than twice the (ULN), or ALT value greater than 10 times the ULN
  • Patients who are required to be on concomitant therapy with IV fat emulsions, such as total parental nutrition (TPN).
  • Patients with total levels > 3 times the upper normal limits (i.e. > 3.0 mg/dl).
  • Patient with Hematopoietic, renal, hepatic and electrolyte disorders (Low level of Magnesium and potassium) will be excluded as per the discretion of Investigator
  • Patients with Clinically significant screening laboratory parameters in the opinion of the investigator.
  • Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable .
  • History of uncontrolled diseases, such as thyroidal dysfunction, angina pectoralis, serious cardiac arrhythmias, serious heart failure, neuropsychiatric infection or disease.
  • Patients with controlled and uncontrolled diabetes mellitus
  • Patients with Uncontrolled hypertension will be excluded.
  • patients will be excluded from participating the study
  • Patients with known positivity for (HIV), and .
  • Positive results for drugs of abuse (benzodiazepines, opioids, amphetamines, cannabinoids, cocaine and barbiturates) in urine.
  • Positive results for alcohol as detected by alcohol breath analyzer.
  • History of difficulty with donating blood or difficulty in accessibility of veins.
  • An unusual or abnormal diet, for whatever reason e.g. religious fasting.
  • History of donation of blood (1 unit or 350 ml) within 90 days prior to receiving the first dose of medicinal product in the study
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    Amphotericin B Liposome

    Amphotericin B Liposome for Injection 50 mg/vial, intravenous infusion at a dose of 3 mg/kg/day, OD for 5 days

    Drug: Amphotericin B Liposome

  • Active comparator
    AmBisome Liposome

    AmBisome Liposome for Injection 50 mg/ vial, intravenous infusion at a dose of 3 mg/kg/day, OD for 5 days

    Drug: AmBisome (Amphotericin B) Liposome

Interventions

06

What researchers measure

Primary outcomes

  1. Estimation of Cmax-ss, Maximum concentration over the steady state dosing interval

    To establish bioequivalence limits within 80-125 %

    Time frame: 05 days

  2. Estimation of AUC0-tau, Area under the plasma concentration time curve over the steady state dosing interval

    To establish bioequivalence limits within 80-125 %

    Time frame: 05 days

Secondary outcomes

  1. Evaluation of Cmin-ss

    Summary statistics, ANOVA, Ratio Analysis, 90% Confidence Interval, Inter subject variability and Power will be calculated

    Time frame: 05 days

  2. Evaluation of Cavg-ss

    Summary statistics, ANOVA, Ratio Analysis, 90% Confidence Interval, Inter subject variability and Power will be calculated

    Time frame: 05 days

  3. Evaluation of tmax-ss

    Summary statistics, ANOVA, Ratio Analysis, 90% Confidence Interval, Inter subject variability and Power will be calculated

    Time frame: 05 days

  4. Evaluation of Cpd

    Summary statistics, ANOVA, Ratio Analysis, 90% Confidence Interval, Inter subject variability and Power will be calculated

    Time frame: 05 days

  5. Evaluation of Percentage Fluctuation

    Summary statistics, ANOVA, Ratio Analysis, 90% Confidence Interval, Inter subject variability and Power will be calculated

    Time frame: 05 days

  6. Evaluation of Swing

    Summary statistics, ANOVA, Ratio Analysis, 90% Confidence Interval, Inter subject variability and Power will be calculated

    Time frame: 05 days

07

Study locations

3 sites
  • International Centre for Diarrhoeal Disease Research b
    Dhaka, 1212, Bangladesh
  • Kala-Azar medical Research Centre
    Muzaffarpur, Bihar 842001, India
  • Rajendra Memorial Research Institute of Medical Sciences
    Patna, Bihar 800007, India
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Apr 2019, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2018
First posted
Aug 17, 2018
StartActual
May 2, 2018
Primary completionActual
Apr 5, 2019
CompletionActual
Apr 5, 2019
Last update
Aug 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03636659
Collaborators
Axis Clinicals Limited
Responsible party
Sponsor
First posted
Aug 17, 2018
Start date
May 2, 2018
Primary completion
Apr 5, 2019
Completion
Apr 5, 2019
Last update
Aug 26, 2019

Study contacts

Nagesh Meda, M.Pharm
study chair · Aurobindo Pharma Ltd
Dr. Subhra Lahiri, Ph.D
study director · Axis Clinicals Limited
Dr. Sajid Mohd, MD
study director · Axis Clinicals Limited
Dr. Krishna Pandey, MD
principal investigator · Rajendra Memorial Research Institute of Medical Sciences
Dr. Shyam Sundar, MD
principal investigator · Kala-Azar medical Research Centre
Dr. Dinesh Mondal, MD
principal investigator · International Centre for Diarrhoeal Disease Research b

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amphotericin B

Start the discussion